Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Switch studies: a review.

R L Murphy1, W J Smith

  • 1Northwestern University, Chicago, IL 60611 USA. r-murphy@northwestern.edu

HIV Medicine
|May 16, 2002
PubMed
Summary
This summary is machine-generated.

Switching from protease inhibitor (PI) regimens to nonnucleoside reverse transcriptase inhibitor (NNRTI) or abacavir-based therapies shows mixed results. While NNRTIs may reduce virologic failure, abacavir carries higher risks with pre-existing mutations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Black Hole Spectroscopy and Tests of General Relativity with GW250114.

Physical review letters·2026
Same author

GW250114: Testing Hawking's Area Law and the Kerr Nature of Black Holes.

Physical review letters·2025
Same author

Cortical stimulation leads to shortened myelin sheaths and increased axonal branching in spared axons after cervical spinal cord injury.

Glia·2023
Same author

Fluorescein diacetate and rapid molecular testing for the early identification of rifampicin resistance in Mali.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2020
Same author

Antibiotics in feed, with special reference to pigs: a veterinary viewpoint.

Animal feed science and technology·2020
Same author

Diabetes Mellitus among new tuberculosis patients in Bamako, Mali.

Journal of clinical tuberculosis and other mycobacterial diseases·2019
Same journal

Correction to 'Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system'.

HIV medicine·2026
Same journal

Ultrasound for the determination of appropriate needle length for intragluteal injection of long-acting rilpivirine-cabotegravir.

HIV medicine·2026
Same journal

History of sexually transmitted infections among mpox cases in the 2022 outbreak in Spain.

HIV medicine·2026
Same journal

Awareness and early implementation of the European AIDS Clinical Society Guidance on statin use in HIV for the primary prevention of cardiovascular disease: A cross-sectional survey of HIV clinicians in Europe.

HIV medicine·2026
Same journal

Ankle brachial index not a reliable tool for risk assessment in people with HIV.

HIV medicine·2026
Same journal

Comparison of four frailty scores to predict adverse health events and mortality in people living with HIV aged 70 years and more (ANRS EP 66 SEPTAVIH study).

HIV medicine·2026
See all related articles

Area of Science:

  • Infectious Diseases
  • Virology
  • Pharmacology

Background:

  • Long-term protease inhibitor (PI)-based antiretroviral therapy (ART) can lead to metabolic changes and adverse effects.
  • Physicians and patients seek alternative ART regimens to manage these issues and improve adherence.

Purpose of the Study:

  • To review data from randomized and cohort studies on switching from PI-based ART to nonnucleoside reverse transcriptase inhibitor (NNRTI) or abacavir-based regimens.
  • To evaluate the virologic and metabolic outcomes of such regimen switches.

Main Methods:

  • Review of randomized controlled trials and cohort studies involving patients switching from PI-based ART.
  • Analysis of virologic failure rates, metabolic parameters, and adverse events.

Related Experiment Videos

Main Results:

  • Switching to NNRTI regimens generally reduced virologic failure frequency.
  • Switching to abacavir-based regimens increased virologic failure risk twofold if reverse transcriptase gene mutations were pre-existing.
  • Improvements in metabolic and lipid abnormalities were inconsistent, though favorable lipid changes were noted with nevirapine.

Conclusions:

  • Switching from PI-based ART to NNRTI or abacavir regimens yields mixed outcomes.
  • NNRTI regimens appear more favorable for virologic control, while abacavir requires careful consideration of baseline mutations.
  • Further research is needed to fully understand long-term metabolic and lipodystrophy outcomes.